Hsbc Holdings PLC Cytom X Therapeutics, Inc. Transaction History

Hsbc Holdings PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$6.6 - $9.0 $104,874 - $143,010	-15,890 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.47 - $7.9 $25,582 - $31,236	3,954 Added 33.13%	15,890 $104,000
Q3 2020 Nov 12, 2020	SELL	$6.55 - $8.83 $12,438 - $16,768	-1,899 Reduced 13.73%	11,936 $80,000
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $5,054 - $9,999	-683 Reduced 4.7%	13,835 $115,000
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $9,321 - $22,205	2,582 Added 21.63%	14,518 $111,000
Q4 2019 Feb 14, 2020	SELL	$5.17 - $8.91 $8,251 - $14,220	-1,596 Reduced 11.79%	11,936 $99,000
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $99,866 - $165,767	13,532 New	13,532 $100,000
Q3 2018 Nov 13, 2018	SELL	$18.04 - $26.41 $175,312 - $256,652	-9,718 Closed	0 $0
Q2 2018 Aug 10, 2018	BUY	$21.38 - $29.68 $207,770 - $288,430	9,718 New	9,718 $222,000

50.4M

112K

8.3K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $58.7M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.